Orion Oyj Series B

Orion and its subsidiaries develop and manufacture pharmaceuticals, active pharmaceutical ingredients and diagnostic tests that are marketed globally. Co. and its subsidiaries have two segments: Pharmaceuticals and Diagnostics. The Pharmaceuticals business develops, manufactures and markets pharmaceuticals and active pharmaceutical ingredients. The Pharmaceuticals business portfolio includes Co.'s Stalevo® (carbidopa, levodopa and entacapone) and Comtess®/Comtan® (entacapone) Parkinson's drugs. The Diagnostics business develops, manufactures and markets diagnostic tests.
  • TickerORNBV
  • ISINFI0009014377
  • ExchangeNasdaq Nordic Helsinki
  • SectorPharmaceuticals & Biotechnology
  • CountryFinland

Analysts

Kimmo Stenvall

ORION - Positive results from darolutamide

Kimmo Stenvall

ORION - Outcome of Darolutamide trials a significant share price driver

Kimmo Stenvall

ORION - Good Q2 report, on the back of Parkinson’s drugs

Expert Corporate Governance Service (ECGS)

Proxy Report - 20/03/2018

In general, Orion is in compliance with the Finnish regulations relating the organisation and procedures of the Annual General Meeting. ECGS recommends to vote in favour of all proposals. There are no further peculiarities.

MarketLine Department

Orion Corporation – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Summary Pharmaceuticals and Healthcare Key Findings Pharmaceuticals and Healthcare Pharmaceuticals and Healthcare Reasons To Buys MarketLine Key Highlights Finland

Kimmo Stenvall

ORION - Positive results from darolutamide

Kimmo Stenvall

ORION - Outcome of Darolutamide trials a significant share price driver

Kimmo Stenvall

ORION - Good Q2 report, on the back of Parkinson’s drugs

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

MarketLine Department

Orion Corporation – Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report

Summary Pharmaceuticals and Healthcare Key Findings Pharmaceuticals and Healthcare Pharmaceuticals and Healthcare Reasons To Buys MarketLine Key Highlights Finland

Expert Corporate Governance Service (ECGS)

Proxy Report - 20/03/2018

In general, Orion is in compliance with the Finnish regulations relating the organisation and procedures of the Annual General Meeting. ECGS recommends to vote in favour of all proposals. There are no further peculiarities.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch